Patents by Inventor Françoise Raynaud

Françoise Raynaud has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • NRP-1 binding inhibitory peptides and uses thereof
    Patent number: 12590122
    Abstract: A number of anti-angiogenic strategies connected with the VEGF signalling pathway are used in current clinical treatment or trial phase, but they either cause adverse effects or are not specific. Various strategies were aimed at identifying peptides inhibiting the VEGF-A165/NRP-1 interaction. A well-known antiangiogenic peptide is the heptapeptide termed “A7R” having the amino acid sequence ATWLPPR, for which various derivatives have been synthesized, which include peptides having the general sequence Lys(hArg)-AA2-AA3-Arg. However, the ability of the known peptides to inhibit the VEGF-A165/NRP-1 interaction was too low for their use as candidate drugs for inhibiting angiogenesis in subjects in need thereof. The present inventors have now conceived a family of novel peptide-like compounds having a nanomolar affinity for NRP-1, which are thus endowed with a powerful capacity to inhibit the VEGF-A165/NRP-1 interaction.
    Type: Grant
    Filed: June 10, 2020
    Date of Patent: March 31, 2026
    Assignees: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), UNIWERSYTET WARSZAWSKI, FONDATION IMAGINE, ASSISTANCE PUBLIQUE—HÔPITAUX DE PARIS, UNIVERSITE DE PARIS
    Inventors: Yves Lepelletier, Françoise Raynaud, Aleksandra Misicka-Kesik, Anna Katarzyna Puszko, Olivier Hermine
  • NRP-1 BINDING INHIBITORY PEPTIDES AND USES THEREOF
    Publication number: 20220169677
    Abstract: A number of anti-angiogenic strategies connected with the VEGF signalling pathway are used in current clinical treatment or trial phase, but they either cause adverse effects or are not specific. Various strategies were aimed at identifying peptides inhibiting the VEGF-A165/NRP-1 interaction. A well-known antiangiogenic peptide is the heptapeptide termed “A7R” having the amino acid sequence ATWLPPR, for which various derivatives have been synthesized, which include peptides having the general sequence Lys(hArg)-AA2-AA3-Arg. However, the ability of the known peptides to inhibit the VEGF-A165/NRP-1 interaction was too low for their use as candidate drugs for inhibiting angiogenesis in subjects in need thereof. The present inventors have now conceived a family of novel peptide-like compounds having a nanomolar affinity for NRP-1, which are thus endowed with a powerful capacity to inhibit the VEGF-A165/NRP-1 interaction.
    Type: Application
    Filed: June 10, 2020
    Publication date: June 2, 2022
    Inventors: Yves Lepelletier, Françoise Raynaud, Aleksandra MISICKA-KESIK, Anna Katarzyna Puszko, Olivier Hermine